JP2024501641A - 置換大環状化合物及び関連する治療方法 - Google Patents

置換大環状化合物及び関連する治療方法 Download PDF

Info

Publication number
JP2024501641A
JP2024501641A JP2023536491A JP2023536491A JP2024501641A JP 2024501641 A JP2024501641 A JP 2024501641A JP 2023536491 A JP2023536491 A JP 2023536491A JP 2023536491 A JP2023536491 A JP 2023536491A JP 2024501641 A JP2024501641 A JP 2024501641A
Authority
JP
Japan
Prior art keywords
formula
another embodiment
ring
alkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501641A5 (enExample
Inventor
ペニントン、ルイス、ディー．
チェ、ヨンギ
フイン、ホアン
アクィラ、ブライアン、エム．
ミッゲ、インゴ、アンドレアス
フー、ユアン
ウッズ、ジェームズ、アール．
レイマー、ブライアン、ケネス
マーティン ベンズィエン、ヨルグ
ワード レーマン、ジョナサン
ハレ、マイケル、アール．
カルラ、シュリニヴァーサ
ヴァリウリン、ロマン、エイ．
マサル、ダルジット
Original Assignee
アルカームス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカームス インコーポレーテッド filed Critical アルカームス インコーポレーテッド
Publication of JP2024501641A publication Critical patent/JP2024501641A/ja
Publication of JP2024501641A5 publication Critical patent/JP2024501641A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023536491A 2020-12-21 2021-12-21 置換大環状化合物及び関連する治療方法 Pending JP2024501641A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063128404P 2020-12-21 2020-12-21
US63/128,404 2020-12-21
US202163190937P 2021-05-20 2021-05-20
US63/190,937 2021-05-20
PCT/US2021/064483 WO2022140316A1 (en) 2020-12-21 2021-12-21 Substituted macrocyclic compounds and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024501641A true JP2024501641A (ja) 2024-01-15
JP2024501641A5 JP2024501641A5 (enExample) 2024-12-24

Family

ID=80050560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536491A Pending JP2024501641A (ja) 2020-12-21 2021-12-21 置換大環状化合物及び関連する治療方法

Country Status (10)

Country Link
US (2) US12006330B2 (enExample)
EP (1) EP4263555A1 (enExample)
JP (1) JP2024501641A (enExample)
KR (1) KR20230127254A (enExample)
CN (1) CN116615427B (enExample)
AU (1) AU2021409403A1 (enExample)
CA (1) CA3172841A1 (enExample)
IL (1) IL303848A (enExample)
MX (1) MX2023005338A (enExample)
WO (1) WO2022140316A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520396A (ja) * 2021-05-26 2024-05-24 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
EP4247801A4 (en) * 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
WO2022232025A1 (en) * 2021-04-26 2022-11-03 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
AU2022281345A1 (en) * 2021-05-26 2023-11-30 Alkermes, Inc. Substituted fused bicyclic macrocyclic compounds and related methods of treatment
CN120584118A (zh) * 2022-11-23 2025-09-02 沃泰克斯药物股份有限公司 食欲素受体2的经取代的大环胺调节剂
JP2026506356A (ja) * 2023-01-31 2026-02-24 ジャズ ファーマシューティカルズ アイルランド リミテッド 大環状オレキシン受容体アゴニスト及びその使用
EP4680611A1 (en) * 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン２受容体アゴニスト
WO2025096445A1 (en) * 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
US20260109711A1 (en) * 2024-09-18 2026-04-23 Vertex Pharmaceuticals Incorporated Macrocyclic sulfonamide modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2020004536A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
JP2023502441A (ja) * 2019-11-25 2023-01-24 アルカームス インコーポレーテッド 置換大環状化合物および関連する治療方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
EP2836485B1 (en) 2012-03-17 2018-01-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
JP6715239B2 (ja) 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
CA2989146A1 (en) 2015-06-12 2016-12-15 Board Of Regents, The University Of Texas System Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN111132975B (zh) 2017-09-28 2023-05-23 勃林格殷格翰国际有限公司 N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
JP7170996B2 (ja) 2017-12-12 2022-11-15 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2019191327A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Ox2r compounds
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
CA3167050A1 (en) 2020-01-10 2021-07-15 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
CN119235864A (zh) 2020-07-17 2025-01-03 卫材R&D管理有限公司 取代的哌啶化合物及其用途
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
WO2022040058A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Cyclopentapyrrole orexin receptor agonists
CN116635393A (zh) 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
WO2022094012A1 (en) 2020-11-02 2022-05-05 Merck Sharp & Dohme Corp. Macrocyclic urea orexin receptor agonists
EP4247801A4 (en) 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12552767B2 (en) 2020-12-03 2026-02-17 Merck Sharp & Dohme Llc 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
US12692262B2 (en) 2020-12-16 2026-07-28 Merck Sharp & Dohme Llc Substituted ureas as orexin receptor agonists
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7860139B2 (ja) 2021-03-03 2026-05-15 リサーチ トライアングル インスティテュート オレキシン受容体アゴニストとしてのアリールスルホンアミド
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
MX2023012971A (es) 2021-05-03 2024-01-16 Jazz Pharmaceuticals Ireland Ltd Agonistas del receptor de orexina y sus usos.
JPWO2022250108A1 (enExample) 2021-05-26 2022-12-01
EP4359387A1 (en) 2021-06-25 2024-05-01 Jazz Pharmaceuticals Ireland Limited Sulfonamide orexin receptor agonists and uses thereof
WO2023017180A1 (en) 2021-08-13 2023-02-16 Orexia Therapeutics Limited Peptide derivatives and related uses as orexin agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
WO2020004536A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
JP2023502441A (ja) * 2019-11-25 2023-01-24 アルカームス インコーポレーテッド 置換大環状化合物および関連する治療方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520396A (ja) * 2021-05-26 2024-05-24 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法

Also Published As

Publication number Publication date
KR20230127254A (ko) 2023-08-31
US20220194958A1 (en) 2022-06-23
AU2021409403A1 (en) 2023-05-25
CA3172841A1 (en) 2022-06-30
IL303848A (en) 2023-08-01
AU2021409403A9 (en) 2025-03-20
CN116615427B (zh) 2025-07-04
CN116615427A (zh) 2023-08-18
US20240368182A1 (en) 2024-11-07
EP4263555A1 (en) 2023-10-25
WO2022140316A1 (en) 2022-06-30
US12006330B2 (en) 2024-06-11
MX2023005338A (es) 2023-05-22

Similar Documents

Publication Publication Date Title
AU2020394444B2 (en) Substituted macrocyclic compounds and related methods of treatment
CN116615427B (zh) 被取代的大环化合物及相关治疗方法
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
US9133122B2 (en) Amide compounds, compositions and uses thereof
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
EP4329877B1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
EP2794593B1 (en) Spiro aminic compounds as orexin antagonists
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
JP2024520395A (ja) 置換される縮合二環式大環状化合物および関連のある治療方法
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
JP6488320B2 (ja) 糖尿病などの疾患の治療用のピロリジンｇｐｒ４０モジュレータ
WO2023249872A1 (en) Substituted fused bicyclic compounds and related methods of treatment
JP2025521508A (ja) 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法
HK40108225A (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40108225B (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40129946A (en) Substituted macrocyclic compounds and related methods of treatment
HK40079289B (en) Substituted macrocyclic compounds and related methods of treatment
HK40079289A (en) Substituted macrocyclic compounds and related methods of treatment
MXPA06004271A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260626